ArticleInternational journal of pediatric endocrinology2015
A randomized pilot trial of growth hormone with anastrozole versus growth hormone alone, starting at the very end of puberty in adolescents with idiopathic short stature.
Article in International journal of pediatric endocrinology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 36 citations in OpenAlex.
- Comparative efficacy of aromatase inhibitors and gonadotropin-releasing hormone analogue in increasing final height of idiopathic short stature boys: a network meta-analysis.Frontiers in endocrinology · 2023Pooled it
- Effect of Antiandrogen, Aromatase Inhibitor, and Gonadotropin-releasing Hormone Analog on Adult Height in Familial Male Precocious Puberty.The Journal of pediatrics · 2017Trial
- Randomized Trial of Aromatase Inhibitors, Growth Hormone, or Combination in Pubertal Boys with Idiopathic, Short Stature.The Journal of clinical endocrinology and metabolism · 2016Trial
- Anastrozole plus leuprorelin in early maturing girls with compromised growth: the "GAIL" study.Journal of endocrinological investigation · 2016Trial
- Combined Letrozole and Growth Hormone Therapy in Late-Pubertal Males with Advanced Bone Age and Open Knee Physes.Children (Basel, Switzerland) · 2026Article
- Near Final Height in Males treated with Aromatase InhibitorsJournal of clinical research in pediatric endocrinology · 2026Article
- Growth Hormone Withdrawal in Mid-Puberty: No Impact on Near Adult Height in Adolescents With Transient Idiopathic GHD.The Journal of clinical endocrinology and metabolism · 2026Article
- Anastrozole Improves Height Outcomes in Growing Children With Congenital Adrenal Hyperplasia Due to 21-hydroxylase Deficiency.The Journal of clinical endocrinology and metabolism · 2025Article
- GH Therapy in Non-Growth Hormone-Deficient Children.Children (Basel, Switzerland) · 2024Review
- Anastrozole vs Letrozole to Augment Height in Pubertal Males With Idiopathic Short Stature: A 3-Year Randomized Trial.Journal of the Endocrine Society · 2024Article
- The effect of anastrozole therapy on final height and sex hormone levels in pubertal boys receiving growth hormone therapy.Archives of endocrinology and metabolism · 2023Article
- Should Skeletal Maturation Be Manipulated for Extra Height Gain?Frontiers in endocrinology · 2021Review
- [Reconsideration of the third-generation non-steroidal aromatase inhibitors in pediatrics].Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences · 2020Article
- [Aromatase inhibitors combined with growth hormone in treatment of adolescent boys with short stature].Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences · 2020Article
- Final adult height of children with idiopathic short stature: a multicenter study on GH therapy alone started during peri-puberty.BMC pediatrics · 2020Article
- Height outcomes in children with growth hormone deficiency and idiopathic short stature treated concomitantly with growth hormone and aromatase inhibitor therapy: data from the ANSWER program.International journal of pediatric endocrinology · 2020Article
- [Clinical effect of letrozole in treatment of idiopathic short stature in adolescent boys].Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics · 2019Article
- The Rationale for Growth Hormone Therapy in Children with Short Stature.Journal of clinical research in pediatric endocrinology · 2017Review
- Erratum to: A randomized pilot trial of growth hormone with anastrozole versus growth hormone alone, starting at the very end of puberty in adolescents with idiopathic short stature.International journal of pediatric endocrinology · 2017Article
- Growing Up with Type 1 Narcolepsy: Its Anthropometric and Endocrine Features.Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine · 2016Article
Corrections and comments
- Erratum issued
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundWhen given during the course of puberty, anastrozole (A), an aromatase inhibitor, has been shown to increase the predicted adult height (PAH) of GH-deficient (GHD) boys treated with recombinant human growth hormone (rhGH). Our study questioned whether this treatment could retain some of its effects in non-GHD adolescent boys if started only at the very end of puberty, a time when rhGH treatment is denied to short adolescents who have almost reached their final height.
objectiveTo explore the effect on adult height of a combination of rhGH and A, compared with rhGH alone, at the end of puberty in boys with idiopatic short stature (ISS).
methodsA prospective randomized study comparing rhGH + A and rhGH was conducted in 24 healthy adolescent boys aged 15.2 ± 1.2 yrs with serum testosterone at adult levels and a faltering growth velocity <3.5 cm/yr leading to a predicted adult height (PAH) <2.5 SDS. Treatments were stopped when growth velocity became <10 mm in 6 months or when height was close to 170 cm. A historical group of ISS adolescents (N = 17) matched for puberty and growth was used for comparison.
resultsIGF1 levels remained within normal limits in all treated patients. Mean treatment duration was 19 months in the rhGH + A group and 11.5 months in the rhGH group (P = 6.10(-4)). Adult height reached 168.4 ± 2.6 cm in the rhGH + A group and 164.2 ± 5.6 cm in the rhGH group (P < 0.02). Adult height was 160.1 ± 2.8 cm in the historical controls.
conclusionA combination of rhGH and A, started at the very end of puberty, seems to allow boys with ISS to reach a greater adult height than rhGH alone. Larger trials are needed to confirm this preliminary observation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.